Esculetin Inhibits Proliferation, Invasion, and Migration of Laryngeal Cancer *In Vitro* and *In Vivo* by Inhibiting Janus Kinases (JAK)-Signal Transducer and Activator of Transcription-3 (STAT3) Activation

B. Geng Zhang  
C. Yi Xu  
F. Hui-fang Zhou

**Background:** Laryngeal cancer is one of the most common malignant tumors of the head and neck. Natural compounds in traditional Chinese medicine provide many valuable potential compounds for tumor chemotherapy. Esculetin, a coumarin derivative from several herbs, inhibits proliferation of many types of cancer cells, but its anticancer effect in laryngeal cancer is still not clear.

**Material/Methods:** We performed *in vitro* proliferation assay, invasion assay, and migration assay to assess the effect of esculetin against LC, and *in vivo* nude mouse xenograft animal model was used as well. Flow cytometry was conducted to analyze the effect of esculetin on cell cycle of LC cells, and Western blot analysis was used to assess the effect of esculetin on the JAK-STAT signaling pathway.

**Results:** Esculetin remarkably inhibits proliferation, migration, and invasion of LC cells, and reduces *in vivo* xenograft tumor growth and tumor weight in a dose-dependent manner. Our molecular mechanism study demonstrated that esculetin significantly inhibits STAT3 phosphorylation and blocks translocation of STAT3 into the nucleus, and esculetin also blocks the cell cycle in G1/S phase.

**Conclusions:** In a summary, by inhibiting the STAT3 activation, esculetin shows potential anticancer effects against the laryngeal cancer.

**MeSH Keywords:** Antigen-Presenting Cells • Head and Neck Neoplasms • STAT3 Transcription Factor

**Abbreviations:** LC – larynx cancer; Esc – esculetin; STAT3 – signal transducer and activator of transcription-3

**Full-text PDF:** [https://www.medscimonit.com/abstract/index/idArt/916246](https://www.medscimonit.com/abstract/index/idArt/916246)
Background

Laryngeal squamous cell carcinoma (or larynx cancer, LC) is a common malignant tumor of the head and neck. LC has the characteristics of concealed location, metastases at early stage, and poor prognosis. There is still no effective screening or early diagnosis method for LC. Laryngeal cancer accounts for 22% of all head and neck malignancies, and the incidence in men is higher than in women. There were approximately 20,000 new cases of laryngeal cancer in China in 2011, with an estimated 11,000 deaths and an incidence rate of 0.35–1.55 per 100,000 population [1]. Males, smokers, and people who drink alcohol, eat red meat, and have HPV infection are at highest risk. Gastroesophageal reflux and laryngitis reflux are also potential risk factors [2].

The treatment methods for laryngeal cancer include surgery, radiotherapy, chemotherapy, and biological target therapy. In recent years, great progress has been made in treating LC. Surgical treatment options have changed from the initial total laryngectomy to the various surgical methods of retaining or reconstructing the larynx, and radiotherapy and chemotherapy are also widely used to treat LC. These changes have important positive significance in improving the survival and life quality of LC patients [3,4].

Drug resistance to chemotherapeutics is a recurrent issue plaguing many cancer treatment regimens and increasing the demand for novel antitumor drugs and new targets of cancer therapy. Natural compounds from traditional Chinese herbs have great potential as leading compounds for cancer chemotherapy. Esculetin (Esc) is a coumarin derivate widely found in natural herbal plants, such as *Cortex fraxini* and *Hymenodictyon excelsum* [5]. Modern pharmacological studies showed that Esc has many pharmacological functions, such as inhibiting 5-lipoxygenase [6], and it has anti-inflammatory [7], anti-oxidation [8], and anti-tumor effects [9]. *In vitro* studies have demonstrated that Esc has antitumor effects, including non-small-cell lung carcinoma (NSCLC) cell lines (NCI-H358 and NCI-H1299) [10], human breast cancer cell line ZR-75-1 [11], human acute myelocytic leukemia cell Kasumi-1 [12], and human leukemia U937G1 cells [13]. Research suggests that Esc has cytotoxicity against many kinds of tumor cells, but the effect of Esc on LC has not been reported.

Signal transducer and activator of transcription-3 (STAT3) is an oncogene which is highly expressed in most tumor tissues and cells [14–16]. Over-expressed STAT3 has been found in various stages of LC development. Its expression and phosphorylation increased with the deterioration of LC [17]. Previous studies have demonstrated that STAT3 is an important mediators of vasculogenic mimicry of squamous cell carcinoma of the larynx, and suppression of the JAK-2/STAT-3 signaling pathway significantly inhibits invasion and vasculogenic mimicry of laryngeal squamous cell carcinoma *in vitro* [18]. Zhang et al. reported that the JAK2 inhibitor AG190 induces cell apoptosis and inhibits proliferation of LC Hep-2 cancer cells [19]. The above evidence suggests STAT3 is a new potential target for the treatment of LC.

This study explored the anti-laryngeal cancer activity of Esc *in vivo* and *in vitro*, as well as its effect on STAT3. Our findings may provide an experimental basis for further research and development of Esc for use in antitumor drugs.

Material and Methods

Cell culture and chemical compounds

Human laryngeal cancer cell lines Hep-2, TU-212, and M4e, and human tubular epithelial cell line HK2 were purchased from the American Type Culture Collection (Manassas, VA USA). The Hep-2, TU-212, and HK2 cells were cultured in RPMI Medium 1640 (Thermo Fisher, Waltham, MA, USA), and M4e cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco; Thermo Fisher, Waltham, MA, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA). Cells were cultured in a 37°C incubator containing 5% CO₂. When growth was in logarithmic phase, cells were seeded onto 96-well plates for further study.

Esculetin was purchased from Sigma-Aldrich (99.99% purity) as 100 mM stock solution, and cisplatin was also purchased from Sigma-Aldrich. STAT3 inhibitor C188-9 was purchased from Selleck Chemicals (Houston, TX, USA) and the STAT3 activator colivelin was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). In an *in vitro* study, Esc, C188-9, and cisplatin were serially diluted with RPMI medium 1640 triple and triple. Final working concentrations were 0.0457, 0.1369, 0.4120, 1.229, 3.700, 11.10, and 33.29 μM and the highest working concentration was 100 μM.

MTT proliferation assay

The MTT assay followed the protocol of a previous study [20]. Cells in logarithmic growth phase were digested with 0.25% trypsin and diluted by medium containing 10% fetal bovine serum into a 5×10⁴/ml cell suspension. Cells were inoculated in 96-well plates with 100 μl per well. Cells were cultured in an incubator at 37°C containing 5% CO₂. We gradually added 100 μl Esc, C188-9, and cisplatin over 24 h; 5 parallel wells of each concentration were prepared, and 100 μl medium culture was added in the blank control group. The cells were cultured in for another 72 h, the supernatant was discarded, and 100 μl MTT was added to each well and cultured for 4 h.
at 37°C. After discarding the supernatant and DMSO (Sigma-Aldrich), the OD value at 570 nm was measured by Labsystems WELLSCAN MK3 ELISA (Dragon, Finland) and the IC₅₀ was calculated. STAT3 inhibitor C188-9 was used as a positive control in the MTT assay. HK2 cells were also used in MTT assay to evaluate the Esc cytotoxicity effect on normal human cells, and cisplatin was used as a positive control for cell cytotoxicity assay.

The growth inhibition rate (%)=(OD value of blank control group–OD value of Esc group)/OD value of blank control group×100%.

**Determination of cellular reactive oxygen species**

Reactive oxygen species (ROS) were assessed using a flow cytometer and DCFH-DA (Sigma-Aldrich) staining. The cells were incubated with 10 μM DCFH-DA at 37°C for 30 min. After incubation with fluorochrome, the cells were washed with phosphate-buffered saline and immediately analyzed by fluorescence microscopy (Observer A1 inverted microscope, ZEISS, Germany). To determine whether ROS production influences Esc cytotoxicity in LC cells, the LC cells were pretreated with 100 μM N-acetyl-l-cysteine (NAC, Sigma-Aldrich) for 2 h, then Esc (IC₅₀ concentration) was added to assess the cell proliferation. LC cells without NAC pretreatment were used as control.

**Migration assay (wound healing assay)**

We used 6-well plates for scratch wound healing assay. At least 3 lines were drawn per well, then we added 6×10⁵ cells to each well and covered them evenly with medium. A vertical line was drawn using a pipette tip (200 μl) after cells were cultured for 24 h. Suspended cells were washed 3 times with PBS. The serum-free medium and drug-free serum-free medium were added. Cells were cultured in an incubator and images were captured 24 h later.

**Cell cycle detection**

After cells in logarithmic growth were cultured for 24 h, medium or Esc with different concentrations were added to culture bottles, with 3 parallel samples in each group. Cells were collected after 48-h culturing, washed with PBS and fixed with 70% cold ethanol, and DNA was analyzed by flow cytometry.

**Matrigel transwell migration**

The invasion of LC cells was measured in Matrigel (Corning, NY, USA)-coated Transwell inserts (Merck Millipore, Darmstadt, Germany) that contained polycarbonate filters with a pore size of 8.0 μm. The inserts were coated with 60 μl Matrigel matrix. We added 100 μl cells with concentration of 5×10⁵/mL into the upper Transwell chambers, and 600 μl medium containing 10% serum and drugs with different concentrations were added to the lower chambers. The cells were cultured for 6 h, then unmigrated cells in the chamber were swabbed after discarding medium. Cells were fixed by 4% polyformaldehyde for 10 min, then stained with crystal violet for 10 min. The filter membrane was photographed under an inverted microscope (200×) after sealing with neutral gum. Cells were counted using Image Pro Plus Version 6 software. We randomly selected 3 wells in each group and 5 vision fields of each well to calculate the average number of cells.

**Xenografts in nude mice**

The 0.2 mL Hep-2 cell suspension (concentration: 6×10⁶/mL) was subcutaneously injected into the axilla of BALB/c male nude mice. Three groups were prepared, with 6 mice in each group, with a 0.5% sodium carboxymethyl cellulose (CMC-Na) solvent control group. Esc was administered at doses of 50 mg/kg and 100 mg/kg. Esc was administered orally for 14 days when the tumor size reached 100 mm³. Esc was added once a day. Tumor volume was measured with a vernier caliper every 3 days. The length of the longest axis (mm) and the length of the tumor were recorded, and the narrowest axis length was taken as the width of the tumor (mm). The volume of the tumor (mm³) was calculated by the following formula: [length (mm)×width (mm)²]/2. After 14 days of treatment, the mice were killed and the tumors were removed and weighed. The tumor inhibition rate was calculated by the following formula: tumor inhibition rate=(W model/W treatment)/W model×100%. W represents the weight of the tumor. In this study, inhibition rate >60% was defined as effective.

**Western blot analysis**

Western blot analysis was performed following the protocol from previous studies [21,22]. Briefly, Esc-treated cells or frozen tumor tissue in liquid nitrogen were used for preparing protein lysates. The frozen tissues were placed in a clean mortar and quickly ground into fine white dry powder. We added 1 ml precooled protein lysate to 100 mg tissues cultured 20 min on ice, then centrifuged at 4°C for 15 min at 12 000 rpm. Proteins were extracted from cytoplasm and nucleus, separately, by nuclear protein extraction kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Protein concentration was measured by BCA protein quantitative assay (Applygen, Beijing, China). We used 50 μg protein of each group to separate protein by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the separated protein was transferred to the polyvinylidene fluoride membrane at room temperature, then closed by 5% BSA for 1 h.
Rabbit anti-mouse primary antibody of STAT3, p-STAT3, Janus kinase-1 (JAK1), p-JAK1, JAK2, and p-JAK2 (1: 1000) were added and reacted overnight at 4°C, then β-actin antibody (1: 2000) was added as control. The horseradish peroxidase labeled antibodies (alkaline phosphatase-labeled goat anti-rabbit antibody, 1: 1000) were added and reacted at room temperature for 2 h. The hybrids of proteins were detected by chemiluminescence chromogenic kit after washing with ECL. Images were captured using the Pierce ECL substrate imprinting detection system (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The integrated optical density of the strip was quantitatively measured using ImageJ software (Bethesda, MD, USA). Expressions of proteins were calculated as expression relative to β-actin.

Data analysis

Continuous variable data are represented as the mean ± standard deviation (SD). SPSS 19.0 software (IBM, Chicago, IL, USA) was used for statistical analysis. The difference between 2 groups was compared with the t test. The differences between multiple groups were compared with the ANOVA with a post hoc t test. P<0.05 was considered to have statistical significance.

Results

Esculetin significantly inhibits the proliferation of laryngeal cancer cells

Cell proliferation assay is commonly used to measure the cytotoxicity of compounds. In the present study, we found that Esc could inhibit the proliferation of 3 LC cell lines, and its inhibitory effect increased with increasing Esc concentrations after 72-h intervention. The inhibitory effect of Esc on Hep-2 cells was the strongest among the 3 LC cell lines whose IC_{50} was 1.958 μM (Figure 1), so the Hep-2 cell line was selected for further study. The IC_{50} of the positive control STAT3 inhibitor C188-9 against all 3 LC cell lines was higher than 10 μM, while the cytotoxicity was weaker than that of esculetin. The IC_{50} of Esc for HK2 cells was higher than 100 μM, and the IC_{50} of cisplatin against LC cells was 7.47 μM for M4e cells, 2.15 μM for Hep-2 cells, and 3.58 μM for TU-212IC cells.

Esculetin-induced cell cytotoxicity is dependent on ROS accumulation

We investigated the role of ROS in mediating Esc-induced cytotoxicity in Hep-2 cells. As shown in Figure 2A, treatment with Esc for 72 h significantly increased intracellular ROS production in Hep-2 cells in a dose-dependent manner, as determined by fluorescence microscopy. Further interference
research demonstrated that Esc cytotoxicity can be largely prevented by pretreatment with NAC (Figure 2B). These data suggest that the increase of cellular ROS was a critical factor underlying Esc-induced cell death.

**Esculetin significantly inhibits the migration of laryngeal cancer cells**

Wound healing assay was used to measure the effect of esculetin on migration ability of LC cells. The inhibitory migration
**Figure 4.** Esc and positive control C188-9 caused G1 phase cell cycle arrest. The cell cycle was significantly blocked in G1 phase in Esc groups (0.5, 2, and 10 μM) compared with the blank control group. At 10 μM concentration, Esc and C188-9 had similar bioactivity to cause cell cycle arrest at G1.

**Figure 5.** Esc and positive control C188-9 decreased the number of invaded cells as determined by Transwell assay. The difference between control and middle and high groups (2 and 10 μM) were significant \((p<0.05)\), and the invasion inhibition rate of Esc was higher than for positive control C188-9 at the same 10 μM concentration.
rates of Hep-2 cells were observed at 24 h after Esc treatment. Typical wound healing at 24 h is shown in Figure 3. At 24 h after scratching, the cell migration rates of the Esc groups were all decreased compared with the control group. The 10 μM group had the highest migration inhibition rate (p<0.05, t test analysis). These results show that Esc inhibited the migration of LC Hep-2 cells. Compared with the positive control STAT3 inhibitor C188-9 at 10 μM, esculetin had a stronger inhibitory effect on LC cell migration.

**Effect of esculetin on the cell cycle of Hep-2**

The cell cycle distribution was analyzed by flow cytometry. Flow cytometry detection of cell cycle showed that at 48 h after Esc and STAT3 inhibitor C188-9 were added into Hep-2 cells, the cell cycle was significantly blocked in G1 phase in Esc groups (0.5, 2, 10 μM) and C188-9 group compared with the blank control group, while the ratio of S/G2 phase cells decreased (Figure 4). At 10 μM, esculetin and C188-9 had almost same bioactivity on G1/S cell cycle arrest.

**Esculetin significantly inhibits laryngeal cancer cell invasion ability**

Compared with the control group, the number of migrated cells in Esc and STAT3 inhibitor C188-9 groups was significantly reduced (p<0.05). There was no significant difference between the control group and the 0.5 μM esculetin group, but the difference between the control group and the middle and high (2 and 10 μM) esculetin groups were significant (p<0.05, Figure 5). Esculetin seems have higher invasion inhibitory ability than C188-9.

**Esculetin significantly inhibits human laryngeal tumor xenografts in nude mice**

The mice had normal reaction, smooth hair, and normal appetite within the first 7 days of administration. The total body weight decreased and the tumor growth increased in the control group from the eighth day onward. These symptoms occurred later (2 weeks after the administration) in Esc groups, and the symptoms of the mice were milder. The size of the tumors in the control group increased significantly. Compared
Figure 7. The relative expressions of total JAK1, JAK2, and STAT 3 protein, and p-JAK1, p-JAK2, and p-STAT 3 after treatment with Esc in Hep 2 cell (A) and xenograft LC tumors in nude mice (B).

Figure 8. The effects of colivelin and C188-9 on esculetin-induced cell proliferation inhibition and p-STAT3 phosphorylation. Hep-2 cells were treated with 5 μM of esculetin and (or) colivelin (1 nM), and C188-9 (0.5 μM) for 48 h. (A) Cell viability of Hep-2 was assessed by MTT assay. (B) STAT3 phosphorylation in Hep-2 cells was modulated by single compound and combination of 2 compounds. Data represent the mean ±SD (* P<0.05, ** P<0.01).
with controls, the tumor volume of the Esc-treated group was significantly decreased (Figure 6).

**Esculetin blocks JAK-STAT3 signaling pathway in vitro and in vivo**

JAK1/2 is the upstream signal of STAT3 [23]. The relative expressions of total JAK1 and total JAK2 in Hep 2 cells (Figure 7A) and tumors (Figure 7B) changed little after being treated with Esc, while the active form, the phosphorylated proteins (pJAK1 and pJAK2), decreased significantly and dose-dependably compared with the untreated control group (P<0.01). In addition, Esc remarkably inhibited phosphorylation of STAT3 in a dose-dependent manner, while total STAT3 did not significantly change. Further analysis showed the level of p-STAT3 in Esc 2 and 10 μM decreased significantly (F=29.750, p<0.001; F=23.183, p=0.048) compared with the control group.

**STAT3 activation reverses the anticancer effects of esculetin on Hep-2 cells**

To further determine whether esculetin inhibits the proliferation of Hep-2 cells and is associated with modulating of STAT3, we used C188-9 (an inhibitor of STAT3) and colivelin (an activator of PI3K). The optimal concentration for C188-9 and colivelin was determined by pre-experiments. The working concentration was 1 nM for colivelin and 0.5 μM for C188-9, and at these concentrations, colivelin and C188-9 did not show cytotoxic effect on Hep-2 cells within 48 h, but both can effectively modulate STAT3 status (Figure 8). Pretreatment of cells with colivelin before esculetin reversed the proliferation inhibitory effects of esculetin, as evidenced by MTT assay (Figure 7). However, combination treatment with esculetin and C188-9 further enhanced the proliferation-inhibitory effect of esculetin. Western blot assay also demonstrated that esculetin combined with C188-9 decreased the STAT3 phosphorylation more effectively than single treatment (Figure 8B). Colivelin also neutralized the ability of Esc to inhibit phosphorylation of STAT3 (Figure 8B). These results together suggest that the anticancer effects of esculetin are mediated by inhibiting the STAT3 signaling pathway.

**Discussion**

In addition to surgery, chemotherapy is the main treatment of laryngeal squamous cell carcinoma (LC), but the adverse reactions of renal toxicity, otoxicity, neurotoxicity, and myelosuppression of chemotherapy are also common. Furthermore, the drug resistance of chemotherapy reactions also makes the treatment of advanced laryngeal cancer less satisfactory. Cortex fraxini is commonly used in traditional Chinese medicine (TCM). The main chemical components of cortex fraxini are coumarin compounds. Cortex fraxini also contains phenols, saponins, tannins, and alkaloids. The aesculin, esculetin, fraxin, and fraxetin in cortex fraxini have obvious anti-inflammatory and analgesic effects [24]. Compelling studies have reported the in vitro and in vivo antitumor and immune regulation of Esc. Esc inhibits cell proliferation of lung cancer cells [25], melanoma cells [26], and human leukemia cells [27]. Esc induces apoptosis of oral squamous cell carcinoma cells through the EGR/Pi3K/Akt signaling pathway and nucleophosmin relocation [28], and also exerts antitumor effect on human gastric cancer cells through the IGF-1/Pi3K/Akt signaling pathway [29]. Kuo et al. demonstrated that Esc enhances the apoptosis effect of paclitaxel on human hepatoma cells HepG2, mediated by the ERK pathway [30].

In this study, the inhibitory effect of Esc on the proliferation of human LC cells was observed by MTT methods. Esc obviously inhibits human Hep-2 cells in a dose-dependent manner. Programmed cell death, or apoptosis, is an important way to control tumor proliferation [31]. Flow cytometry showed the cell cycle of Hep-2 cells was disturbed by Esc, the number of cells in G1 phase increased, and the number of cells in S/G2 phase decreased, which inhibited the proliferation of tumor cells in vitro. Turkekul et al. [32] demonstrated esculetin inhibits the survival of human prostate cancer cells by inducing apoptosis and caused G1 phase cell cycle arrest. These results are consistent with our research. Further analysis showed that downregulation of CDK2, CDK4, and cyclin D1 and upregulation of p53, p21Cip1, and p27Kip1 are involved in the process by which esculetin acts as a tumor suppressor in regulating the cell cycle in prostate cancer cells.

Our in vivo research shows that Esc has inhibitory effects on tumor mass and tumor volume in male tumor-bearing mice. Compared with the model group, Esc significantly inhibited the growth of tumors, reaching 80%. In a recent study performed in tumor-bearing mice, Esc exerted antitumor ability through enhancing the immune adhesion ability of erythrocytes to tumor cells [33], which demonstrates that erythrocyte immunity might be one of the mechanisms of by which Esc acts.

ROS are chemically reactive molecules that are constantly generated and eliminated during diverse biological and cellular reactions, and upregulated and redundant ROS are highly toxic to cells because of their peroxidative activity toward biological constituents [34]. Consistent with previous studies, we also demonstrated that Esc induces ROS production. After co-treatment with ROS scavenger, the LC cell proliferation inhibitory capability of Esc was significantly reduced, which suggests that ROS-mediated cytotoxicity is one of mechanisms for its anticancer effect.

Janus kinases (JAK) is a class of non-transmembrane tyrosine kinase that phosphorylate the cytokine receptors and a number
of signal molecules containing specific SH2 domains. The JAK protein family includes 4 members: JAK1, JAK2, JAK3, and Tyk2 [35]. Signal transduction and activators of transcription (STAT) is a signal transducer or activator of transcription. Currently, 7 members of the STAT family have been found: STAT1-STAT4, STAT5a, STAT5b, and STAT3 [36]. Among them, the most conservative and functional section on sequences is the SH2 domain [37]. JAK catalyzes the phosphorylation of STAT protein on the receptor, and the activated STAT protein enters the nucleus in the form of 2 polymers, binding to the target gene and regulating the transcription of the gene [38]. The activation of STATs in normal cells is fast and transient, while STATs is persistently activated in tumor cells.

The JAK/STAT tyrosine kinase signal pathway was first discovered in interferon-induced signal transduction of cells. As an important pathway for cytokine signaling, JAK/STAT is activated by a variety of cytokines, growth factors, and receptors, and it participates in the processes of cell proliferation, differentiation, proliferation, apoptosis, angiogenesis, and immune regulation. Disrupted JAK-STAT signaling can lead to a variety of diseases, such as skin conditions, cancers, and disorders of the immune system.

STAT3 can be activated by a variety of growth factor and inflammatory signals, and research indicates STAT 3 is implicated in both primary and acquired resistance to chemotherapy [39]. Activation of STAT3 is mediated by a number of tyrosine kinases. We found that activated STAT3 is downregulated with decreased phosphorylation of JAK1 and JAK2 in Esc-treated LC cells or tissues. By co-treatment with STAT3 inhibitor or activator, our data suggest that Esc targeting these pathways in LC are likely via STAT3.

In addition to inhibiting phosphorylation of JAK1, JAK2, and STAT3, research demonstrated Esc can reverse the abnormal pattern of lipid peroxidation, antioxidants, and detoxification agents in 7,12-Dimethylbenz(a)anthracene (DMBA)-induced hamster buccal pouch carcinogenesis as compared to control hamsters [40]. Kim et al. also demonstrated that Esc suppresses tumor growth and metastasis by targeting the Axin2/E-cadherin axis in colorectal cancer cells and in a mouse model [41]. Taken together, these results suggest that there might be more tumor signaling pathways and targets involved in the antiangiogenic activity of Esc in cancer. Traditional Chinese medicine mainly focuses on the anti-inflammatory and analgesic effects of Esc. With more and more reported anticancer effects of Esc, future clinical research is essential.

Conclusions

In summary, our research shows Esc inhibits the proliferation, migration, and survival of human LC Hep-2 cells, and Esc induces apoptosis of LC cells and causes G1 phase cell cycle arrest. In vivo results also indicated Esc inhibits the growth of LC xenografts in nude mice. Esculetin exerts its antitumor effect on LC cancer through the JAK/STAT signaling pathway.

Ethics statement

The animal protocol was approved by the Institutional Animal Care and Use Committee of Tianjin Medical University General Hospital, China.

Conflicts of interest

None.

References:

1. Du L, Li H, Zhu C et al: Incidence and mortality of laryngeal cancer in China, 2011. Chin J Cancer Res, 2015; 27: 52–58
2. Steuer CE, El-Deiry W, Parks JR et al: An update on larynx cancer. Cancer J Clin, 2017; 67: 31–50
3. Johnson JT: Individualized treatment of laryngeal cancer. JAMA Otolaryngol Head Neck Surg, 2017; 143: 367
4. Garcia Lorenzo J, Montoro Martinez V, Rigo Quera A et al: Modifications in the treatment of advanced laryngeal cancer throughout the last 30 years. Eur Arch Otorhinolaryngol, 2017; 274: 3449–55
5. Liang C, Ju W, Pei S et al: Pharmacological activities and synthesis of esculetin and its derivatives: A mini-review. Molecules, 2017; 22: pii: E387
6. Kwon OS, Choi JS, Islam MN et al: Inhibition of 5-lipoxygenase and skin inflammation by the aerial parts of Artemisia capillaris and its constituents. Arch Pharm Res, 2011; 34: 1561–69
7. Hu Y, Chen X, Duan H, Hu Y, Mu X: Chinese herbal medicinal ingredients inhibit secretion of IL-6, IL-8, E-selectin and TXB2 in LPS-induced rat intestinal microvascular endothelial cells. Immunopharmacol Immunotoxicol, 2009; 31: 550–55
8. Wang C, Pei A, Chen J et al: A natural coumarin derivative esculetin offers neuroprotection on cerebral ischemia/reperfusion injury in mice. J Neurochem, 2012; 121: 1007–13
9. Park SS, Park SK, Lim JH et al: Esculetin inhibits cell proliferation through the Ras/ERK1/2 pathway in human colon cancer cells. Oncol Rep, 2011; 22: 253–259
10. Lee RH, Jeon YJ, Cho JH et al: Esculetin exerts anti-proliferative effects against non-small-cell lung carcinoma by suppressing specificity protein 1 in vitro. Gen Physiol Biophys, 2017; 36: 31–39
11. Chang HT, Chou CT, Lin YS et al: Esculetin, a natural coumarin compound, evokes Ca(2+) movement and activation of Ca(2+)-associated mitochondrial apoptotic pathways that involved cell cycle arrest in ZR-75-1 human breast cancer cells. Tumour Biol, 2016; 37: 4665–78
12. Sawney S, Arora R, Aggarwal KK, Saluja D: Esculetin downregulates the expression of AML1-ETO and C-Kit in Kasumi-1 cell line by decreasing half-life of mRNA. J Oncol, 2015; 2015: 781473
13. Lee SH, Park C, Jin CY et al: Involvement of extracellular signal-related kinase signaling in esculetin induced G1 arrest of human leukemia U937 cells. Biomed Pharmacother, 2008; 62: 723–29
14. Tong M, Wang J, Jiang N et al: Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis. PLoS One, 2017; 12: e0182282
15. Ji K, Zhang M, Chu Q et al: The Role of p-STAT3 as a prognostic and clinicopathological marker in colorectal cancer: a systematic review and meta-analysis. PLoS One, 2016; 11: e0160125

16. Banerjee K, Resat H: Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer, 2016; 138: 2570–78

17. Qu S, Song Y, Mei JY et al: Li:17 and its receptors regulate JAK/STAT3 signaling pathway and promote angiogenesis in laryngeal carcinoma. Acta Universitatis Medicinalis Anhui, 2015; 50: 1464–67

18. Hu A, Huang J, Jin XJ et al: Curcumin suppresses invasiveness and vasculo-genic mimicry of squamous cell carcinoma of the larynx through the inhibition of JAK-2/STAT-3 signaling pathway. Am J Cancer Res, 2015; 5: 278–88

19. Zhang H, Zhang D, Luan X et al: Inhibition of the signal transducers and activators of transcription (STAT) signaling pathway by AG490 in laryngeal carcinoma cells. J Int Med Res, 2010; 38: 1673–81

20. Sen Z, Zhan XK, Jing J et al: Chemosensitizing activities of cyclotides from Clitoria ternatea in paclitaxel-resistant lung cancer cells. Oncol Lett, 2013; 5: 641–44

21. Zhang S, Yang J, Li H et al: Skimmia, a coumarin, suppresses the streptozotocin-induced diabetic nephropathy in wistar rats. Eur J Pharmacol, 2012; 692: 78–83

22. Zhang S, Xin H, Li Y et al: Skimmia, a coumarin from hydrangea paniculata, slows down the progression of membranous glomerulonephritis by anti-inflammatory effects and inhibiting immune complex deposition. Evid Based Complement Alternat Med, 2013; 2013: 819296

23. Fang J, Chu L, Li C et al: JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway. Oncol Rep, 2015; 33: 494–502

24. Li L, Wang X: [Progress of pharmacological research on icari.] China Journal of Chinese Materia Medica, 2008; 33: 2732–36 [In Chinese]

25. Lacy A, O’Kennedy R: Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des, 2004; 10: 3797–811

26. Jeon YI, Jang JY, Shim JH et al: Esculetin, a coumarin derivative, exhibits anti-proliferative and pro-apoptotic activity in G361 human malignant melanoma. J Cancer Prev, 2015; 20: 106–12

27. Rubio V, Garcia-Perez AI, Tejedor MC et al: Esculetin neutralises cytotoxicity of t-BHP but not of H2O2 on human leukaemia NB4 cells. Biomed Res Int, 2017; 2017: 9491045

28. Jeon YI, Cho JH, Lee SY et al: Esculetin induces apoptosis through EGFR/PI3K/Akt signaling pathway and nucleophosmin relocalization. J Cell Biochem, 2016; 117: 1210–21

29. Wang G, Lu M, Yao Y et al: Esculetin exerts antitumor effect on human gastric cancer cells through IGF-1/PI3K/AKT signaling pathway. Eur J Pharmacol, 2017; 814: 207–15

30. Kuo HC, Lee HL, Hu CC et al: Enhancement of esculetin on Taxol-induced apoptosis in human hepatoma HepG2 cells. Toxicol Appl Pharmacol, 2006; 210: 55–62

31. Monian P, Jiang X: The cellular apoptosis susceptibility protein (CAS) promotes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis and cell proliferation. J Biol Chem, 2016; 291: 2379–88

32. Turkekul K, Colpan RD, Baykul T et al: Esculetin inhibits the survival of human prostate cancer cells by inducing apoptosis and arresting the cell cycle. J Cancer Prev, 2018; 23: 10–17

33. Xu RD, Shao T, Ila SH: [Effect of esculetin on immune function of red cell in tumor bearing mice.] Journal of Harbin University of Commerce (Natural Sciences Edition), 2016; 32: 146–53 [In Chinese]

34. Pan H, Wang BH, Lu W et al: Esculetin induces apoptosis in human gastric cancer cells through a cyclophilin D-mediated mitochondrial permeability transition pore associated with ROS. Chem Biol Interact, 2015; 242: 51–60

35. Vier J, Groth M, Sochalska M, Kirschnek S: The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling. Cell Death Dis, 2016; 7: e2103

36. Banerjee S, Biehl A, Gadina M et al: JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects. Drugs, 2017; 77: 521–46

37. Borges S, Mouldou E, Vouyovitch C et al: Involvement of a JAK/STAT pathway inhibitor: Cytokine inducible SH2 containing protein in breast cancer. Adv Exp Med Biol, 2008; 617: 321–29

38. Pencik J, Pham HT, Schmoellerl J et al: JAK-STAT signaling in cancer: From activators of transcription (STAT) 3 signalling pathway by AG490 in laryngeal carcinoma. Acta Universitatis Medicinalis Anhui, 2015; 50: 1464–67

39. Borges S, Mouldou E, Vouyovitch C et al: Involvement of a JAK/STAT pathway inhibitor: Cytokine inducible SH2 containing protein in breast cancer. Adv Exp Med Biol, 2008; 617: 321–29

40. Selvasundaram R, Manoharan S, Buddhan R et al: Chemopreventive potential of esculetin in 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis. Mol Cell Biochem, 2018; 448(1–2): 145–53

41. Kim WK, Byun WS, Chung HJ et al: Esculetin suppresses tumor growth and metastasis by targeting Axin2/E-cadherin axis in colorectal cancer. Biochem Pharmacol, 2018; 152: 71–83